Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley Purchases 8,600 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley purchased 8,600 shares of the firm’s stock in a transaction dated Thursday, April 25th. The stock was acquired at an average price of $3.24 per share, for a total transaction of $27,864.00. Following the purchase, the senior vice president now owns 188,718 shares in the company, valued at approximately $611,446.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $3.26 on Friday. Abeona Therapeutics Inc has a twelve month low of $2.83 and a twelve month high of $9.01. The stock has a fifty day simple moving average of $7.31 and a 200 day simple moving average of $5.61.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). Research analysts predict that Abeona Therapeutics Inc will post -2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $36.00 price objective on shares of Abeona Therapeutics in a report on Tuesday. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC bought a new position in Abeona Therapeutics during the fourth quarter worth $199,000. Worth Venture Partners LLC lifted its stake in shares of Abeona Therapeutics by 76.6% in the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Abeona Therapeutics by 84.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after purchasing an additional 1,488,834 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Abeona Therapeutics in the third quarter worth approximately $648,000. Finally, AIGH Capital Management LLC lifted its stake in Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after buying an additional 496,278 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.